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Abstract 
Opioids are effective analgesic agents but serious adverse effects such as tolerance and 
withdrawal contribute to opioid dependence and limit their use. Opioid withdrawal involves 
numerous brain regions and includes suppression of dopamine release and activation of 
neurons in the ventral striatum. By contrast, acute opioids increase dopamine release. Like 
withdrawal, acute opioids also activate neurons in the ventral striatum, suggesting that 
different populations of ventral striatal neurons may be activated by withdrawal and acute 
opioid actions. Here, immunofluorescence for the activity-related immediate-early gene, c-
Fos, was examined in transgenic reporter mouse lines by confocal microscopy to study the 
specific populations of ventral striatal neurons activated by morphine withdrawal and acute 
morphine. After chronic morphine, naloxone-precipitated withdrawal strongly increased 
expression of c-Fos immunoreactivity, predominantly in D2-receptor (D2R) medium-sized 
spiny neurons (MSNs) of the nucleus accumbens (NAc) core and shell regions. By contrast, 
a single injection of morphine exclusively activated c-Fos immunoreactivity in D1-receptor 
expressing (D1R) MSNs of the core and shell of the NAc. These results reveal a striking 
segregation of neuronal responses occurring in the two populations of MSNs of the NAc in 
response to morphine withdrawal and acute morphine. 
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1. Introduction 
Clinical use of opioids is limited and illicit use exacerbated by adverse effects that include 
development of tolerance and withdrawal during chronic use (Williams et al., 2001). Abrupt 
cessation of chronic opioid use produces an intense withdrawal syndrome manifested by 
dysphoric and aversive signs in both humans and animal models (Williams et al., 2001), 
which contributes to drug seeking and high rates of relapse (Koob et al., 1992). It is well 
established that different components of the global withdrawal response arise from distinct 
structures in the brain (Maldonado et al., 1992; Williams et al., 2001; Hyman et al., 2006). 
Among these the ventral tegmental area (VTA) and nucleus accumbens (NAc) are thought 
to contribute to the aversive signs of opioid withdrawal (Koob et al., 1989; Stinus et al., 
1990; Gracy et al., 2001). Opioid withdrawal is associated with decreased activity of 
dopaminergic neurons and decreased dopamine output to the NAc (Pothos et al., 1991; 
Rossetti et al., 1992; Diana et al., 1995; Mazie-Robison et al., 2011), and is also associated 
with strong induction of the activity-related immediate early gene, c-Fos, in neurons of the 
NAc after precipitation of withdrawal (Hayward et al., 1990; Rasmussen et al., 1995; 
Georges et al., 2000; Gracy et al., 2001; Hamlin et al., 2001; Bagley et al., 2011). 
Conversely, acutely administered opioids increase activity of dopaminergic neurons in the 
ventral tegmental area (VTA) (Diana et al., 1995; Johnson and North, 1992) and increase 
dopamine release in the NAc (Pothos et al., 1991), an effect that is thought to mediate 
reward (Hyman et al., 2006). Acute opioids also increase c-Fos expression in neurons of 
the NAc (Chang et al., 1988; Liu et al., 1994; Garcia et al., 1995; Bontempi and Sharp, 
1997; Taracha et al., 2006).  
 
The finding that both naloxone-precipitated opioid withdrawal and acute morphine 
administration increased c-Fos expression in NAc, despite their opposing effects on 
dopamine release and aversion, suggests that different populations of MSNs may be 
involved. Most neurons in the striatum and the NAc (∼95%) are GABAergic medium-sized 
spiny neurons (MSNs) (Kawaguchi, 1997), and are subdivided into two intermingled 
populations according to their projection targets and their selective expression of dopamine 
receptor types (Gerfen et al., 1990). Striatonigral MSNs express D1-type receptors (D1Rs) 
and constitute the ‘direct-pathway’ of the basal ganglia, whereas striatopallidal MSNs 
express D2-type receptors (D2Rs) and constitute the ‘indirect-pathway’ (Alexander et al., 
1986; Gerfen et al., 1990).  
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Previous double in situ hybridization studies of c-fos, D1R and preproenkephalin mRNAs in 
rats found considerable overlap in induction of c-fos in NAc striatonigral and striatopallidal 
populations during opioid withdrawal (Georges et al., 2000). More recently, bacterial 
artificial chromosome (BAC) transgenic animals with targeted expression of eGFP in D1R 
(drd1a-eGFP mouse) and D2R (drd2-eGFP) expressing MSNs (Gong et al., 2003) have 
been used to unequivocally identify D1R (striatonigral) and D2R (striatopallidal) expressing 
MSNs (Valjent et al., 2009; Bertran-Gonzalez et al., 2010). This approach has identified 
strong functional segregation among striatonigral and striatopallidal populations in response 
to drugs selectively acting on D1Rs and/or D2Rs (Valjent et al., 2009). The present study 
therefore used these two BAC transgenic lines to determine if D1R or D2R expressing 
populations of NAc MSNs are differentially activated by opioid withdrawal. The effects of 
naloxone-precipitated opioid-withdrawal, as well as acute morphine, on the co-localization 
of c-Fos immunoreactivity and eGFP were examined by confocal microscopy in different 
territories of the NAc. A striking segregation of the neuronal populations engaged in the two 
opioid-related responses was observed. Naloxone-precipitated morphine withdrawal 
induced c-Fos expression predominantly in D2R MSNs, whereas acute morphine induced 
c-Fos expression exclusively in D1R MSNs. 
 
2. Materials and Methods 
2.1 Animals 
A total of 28 male adult reporter mice (Swiss-Webster) carrying drd2-eGFP or drd1a-eGFP 
bacterial artificial chromosome (BAC) transgenes were used in this study (Gene Expression 
Nervous System Atlas; Gong et al., 2003). Mice were kept in flow-regulated home cages 
(Tecniplast Smart Flow) in stable conditions of temperature (21°C) and humidity (50%), and 
were maintained under a 12 h light/dark cycle with food and water ad libitum. All 
experiments were performed according to the ethical guidelines of the National Health and 
Medical Research Council of Australia and were approved by the University of Sydney 
Animal Care and Ethics Committee.  
2.2 Drugs and drug administration protocols 
Morphine dependence and naloxone-precipitated withdrawal. Physical dependence to 
morphine was induced over a six-day period by three injections of a sustained-release 
morphine (free base) emulsion (300 mg/kg, GlaxoSmithKline Australia) on alternate days 
(days 1, 3 and 5) as described previously (Hacker et al., 2006; Bagley et al., 2011). Briefly, 
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mice were transiently anesthetized with isoflurane prior to morphine injections. The 
morphine base was suspended in a vehicle comprising 50% saline, 40% light liquid paraffin 
and 10% mannide monooleate, warmed and injected s.c. at three different sites. This 
sustained release preparation, originally developed by Collier et al. (1972) has been 
extensively used to produce sustained morphine actions for several days and opioid 
tolerance, and dependence without the need to subject animals to invasive surgery (e.g. 
Hacker et al., 2006; Chieng et al., 2005; Bagley et al., 2011).  On day 6, opioid withdrawal 
was precipitated by injecting naloxone (5 mg/kg i.p.) or its vehicle (isotonic saline). 
Withdrawn mice were then kept in separate cages and perfused two hours after the 
injection. To avoid the possibility of novelty or stress-induced induction of c-Fos in NAc, 
opioid withdrawal signs were not explicitly scored in separate observation chambers in the 
present study (Hebb et al., 2004). Nonetheless, withdrawal signs appeared comparable to 
those we have reported recently with the same treatment schedule (Hacker et al., 2006; 
Chieng et al., 2005; Bagley et al., 2011). These included jumps, wet dog shakes, paw 
tremor, teeth chattering, ptosis, weight loss and diarrhea (e.g. Suppl. Table 1 in Bagley et 
al., 2011).  Control mice were subjected to the morphine dependence protocol but were 
perfused on day 6 without induction of naloxone-precipitated withdrawal, either without 
injection or following injection of vehicle (see Fig. 2A).  
Acute morphine protocol. A supramaximal locomotor stimulatory (e.g. Bohn et al., 2003) but 
non-toxic (e.g. Sora et al., 2001) dose of morphine-HCl (Acute morphine; 50 mg/kg, 
GlaxoSmithKline Australia) or vehicle (Control; 0.9% (w/v) NaCl) was injected s.c. 2 h prior 
to processing for immunofluorescence.  
2.3 Tissue processing 
Mice were rapidly anaesthetized with lethabarb (300 mg/kg, i.p., Virbac) and transcardially 
perfused with 4% (w/v) paraformaldehyde in 0.1 M sodium phosphate buffer (pH 7.5). 
Brains were post-fixed overnight in the same solution and stored at 4°C. Unfrozen 30-µm 
thick sections were cut with a vibratome (VT1000, Leica Microsystems) and stored at -30°C 
in a solution containing 30% (vol/vol) ethylene glycol, 30% (vol/vol) glycerol and 0.1 M 
sodium phosphate buffer, until they were processed for immunofluorescence. Brain regions 
were identified using a mouse brain atlas (Dong, 2008), and sections close to three rostro-
caudal coordinates (1.42, 1.145 and 0.945 mm from Bregma) were selected for 
immunofluorescence.  
2.4 Immunofluorescence 
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eGFP and DARPP-32 detection. Free-floating sections were rinsed three times (10 min 
each) in Tris-buffered saline (TBS; 0.25 M Tris and 0.5 M NaCl, pH 7.5), incubated for 5 
min in TBS containing 3% H2O2 and 10% methanol (v/v), and then rinsed three times for 10 
min each in TBS. After 20 min incubation in 0.2% Triton X-100 in TBS, sections were rinsed 
three times in TBS again, and were incubated overnight at 4°C with purified mouse 
monoclonal anti-DARPP-32 antibodies (1:500, BD Transduction Laboratories) in TBS. The 
next day, sections were then rinsed three times for 10 min in TBS and incubated for 45 
minutes at room temperature with goat Cy3-coupled secondary antibodies (1:400, 
Invitrogen). Sections were finally rinsed for 10 min twice in TBS and twice in TB (0.25 M 
Tris) before mounting in Vectashield (Vector Laboratories) fluorescence medium. 
eGFP and c-Fos detection. Free-floating sections were rinsed three times (10 min each) in 
phosphate-buffered saline (PBS; 0.1M, pH 7.5) and blocked and permeabilized at room 
temperature for 2 h in PBS containing 10% normal goat serum (NGS) and 0.5% Triton-
X100. Sections were then incubated for 48 h at 4°C with polyclonal rabbit anti-c-Fos 
primary antibody (1:500, Santa Cruz Biotechnology, Inc) in PBS with 2% NGS and 0.2% 
Triton-X100. Unbound primary antibodies were washed in PBS (3 rinses, 10 min each) prior 
to 90 min incubation with Cy3-conjugated goat anti-rabbit secondary antibody (1:1000, 
Molecular Probes) in PBS with 2% NGS and 0.2% Triton X-100 at room temperature. In 
sections from drd1a-eGFP mice, polyclonal chicken anti-eGFP primary antibodies (1:500, 
Aves Lab, Inc) and FITC-conjugated goat anti-chicken antibodies (1:1000, Jackson 
ImmunoResearch Laboratories, Inc) were added to the primary and secondary antibody 
incubations, respectively. Sections were rinsed 3 times in PBS (10 min) before mounting in 
Fluoromount-G (SouthernBiotech) fluorescence medium. 
2.5 Fluorescence imaging and quantification 
Double-labeled images were obtained with a sequential laser scanning confocal 
microscope (Olympus Fluoview FV300, BX61WI microscope) using a 60X objective (UPFL 
60X oil). In the c-Fos study, 10 image stacks of 235.47 µm2 (step size: 2 µm) were 
sequentially taken for green FITC/eGFP fluorescence (channel 01, Ar laser intensity usually 
20.0%; PMT: 700v; offset: 3%) and red CY3 fluorescence (channel 02, HeNe green laser 
intensity usually 20.0%; PMT: 720v; offset 3%). For each of the 3 rostro-caudal sections 
analyzed, image stacks were acquired bilaterally per region, so a total of 12 stacks were 
obtained per individual (see Fig. 1). The total number c-Fos expressing neurons was first 
assessed by identifying all immunoreactive cells in each stack (channel 02). Stacks were 
then overlapped with the corresponding eGFP series of images (channel 01). The number 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
7 
 
of c-Fos and eGFP co-localized neurons was then re-quantified, and the number of non co-
localized neurons was obtained as the total number minus the number of co-localized 
neurons. Final numbers are the sum of counted neurons per hemisphere. Total values from 
each hemisphere were finally averaged per individual. 
2.6 Statistical analyses 
Data are expressed as mean values ± SEM (n = 3-4 animals per group), and were 
analyzed using two-way ANOVA. Post hoc comparisons between groups were made using 
Bonferroni multiple comparison test. In all cases, significance threshold was set at p < 0.05. 
Statistical analysis was performed with PRISM 5.0 software (GraphPad, Inc). 
 
3. Results 
3.1 drd2-eGFP BAC transgenic mice provide clear identification of the two MSN populations 
in the NAc core and shell 
BAC transgenic mice have been established as a very good tool for the identification of the 
two main MSN populations in the striatum (Valjent et al., 2009; Bertran-Gonzalez et al., 
2010). drd2-eGFP mice are particularly useful because accurate distinction of D2R neurons 
is possible without any method of signal amplification, due to their high intensity of 
fluorescence (Matamales et al., 2009). Confocal microscopy on drd2-eGFP mice combined 
with DARPP-32 immunostaining, a reliable marker of both populations of MSNs (Ouimet et 
al., 1984; Matamales et al., 2009), was used to systematically identify D2R neurons in 
regions unambiguously comprised within the NAc core and the NAc shell at three different 
rostro-caudal levels (Fig. 1A). Fluorescence in these mice was confined to the striatum and 
olfactory tubercle (Fig. 1B), and very clearly identified D2R neurons in the selected NAc 
core and NAc shell regions at a higher magnification (Fig. 1B, insets 1 and 2). Double 
staining with DARPP-32, revealed that approximately half of the neurons expressed eGFP 
in both selected regions (Fig. 1C and D), confirming the accuracy of drd2-eGFP mice for 
the identification of not only D2R neurons (those expressing fluorescence) but also D1R 
neurons (those lacking fluorescence) (Matamales et al., 2009).  
3.2 Naloxone-precipitated opioid withdrawal induces c-Fos expression very selectively in 
D2R MSNs of drd2-eGFP mice 
Induction of c-Fos expression has long been related to neuronal activation (Sheng and 
Greenberg, 1990; Hughes and Dragunow, 1995), and has been shown to occur in striatal 
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neurons in response to multiple pharmacological treatments, especially those engaging 
D1Rs and D2Rs (Robertson et al., 1991; Young et al., 1991; Berretta et al., 1992; Moratalla 
et al., 1996). In the NAc, acute morphine injections induce strong c-Fos expression in 
striatal neurons (Chang et al., 1988; Garcia et al., 1995; Taracha et al., 2006), and this 
activation is dependent upon D1, NMDA and µ-opioid (MOR) receptors (Liu et al., 1994; 
Bontempi and Sharp, 1997). Naloxone-precipitated morphine withdrawal induces high 
levels of c-Fos expression in striatal neurons, an effect that is particularly strong in the NAc 
but less prominent in the dorsal striatum (Hayward et al., 1990; Rasmussen et al., 1995; 
Georges et al., 2000; Gracy et al., 2001). 
The treatment schedule used here has consistently been reported to induce intense 
naloxone-precipitated withdrawal behavior (see Methods, e.g. Bagley et al., 2011). The 
effect of naloxone-precipitated withdrawal on c-Fos expression was first examined in the 
NAc of drd2-eGFP mice (Fig. 2). c-Fos expression was greatly enhanced in NAc core and 
shell 2 hours after injection of naloxone compared to controls, and almost all 
immunoreactivity was confined to D2R+ neurons (Fig. 2B-D). No differences in basal c-Fos 
expression were observed between uninjected and vehicle challenged mice (Fig. 2C, D). In 
a separate experiment (Bagley et al., 2011), we also observed low levels of basal c-Fos 
expression in NAc and no significant differences between three control groups (all n = 6), 
including chronic vehicle/saline challenge (18 ± 3 c-Fos positive neurons per series in NAc 
shell), chronic vehicle/naloxone challenge (20 ± 3) and chronic morphine/saline challenge 
(13 ±2).  
During withdrawal, c-Fos immunoreactivity was profoundly elevated (319 ± 32.1 neurons, n 
= 4 vs. 51.5 ± 20.7, n = 4, p < 0.001) throughout the rostro-caudal extent of the NAc (see 
Fig. 1A for rostro-caudal levels sampled). A large, significant increase of c-Fos expression 
occurred in D2R+ (~9-fold) versus D2R- neurons in both the NAc core and shell, whereas a 
smaller increase (~3 fold) was observed in D2R- neurons (Fig. 2C and D), which was 
significant (P < 0.05) only in the NAc core. The increase of c-Fos expression in D2R+ 
neurons was significantly greater than D2R- neurons in both NAc core and shell (Fig. 2C 
and D). 
3.3 Naloxone-precipitated opioid withdrawal induces c-Fos expression selectively in 
(presumed) D2R MSNs of drd1a-eGFP mice 
Recent studies have reported several behavioral and physiological alterations in drd2-eGFP 
mice (Kramer et al., 2011) that could potentially influence opioid withdrawal effects on NAc 
neurons. It was also not possible to rule out whether or not the trend for withdrawal-induced 
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c-Fos in D2R- neurons could include the small populations of NAc non-MSNs in drd2-eGFP 
mice (Kawaguchi, 1997). The next experiment therefore sought to confirm the distribution of 
naloxone-induced c-Fos expression found in D2R MSNs by using drd1a-eGFP BAC 
transgenic mice (Fig. 3), another reporter line that specifically tags D1R expressing 
population of striatal MSNs with no major physiological alterations. After application of the 
same naloxone-precipitated withdrawal procedure to drd1a-eGFP mice (see Fig. 2A), the 
pattern of c-Fos immunoreactivity distribution in the NAc largely matched that found in drd2-
eGFP mice. As found in the drd2-eGFP mice, withdrawal-induced increased c-Fos was 
largely confined to presumed D2R expressing (D1R-) neurons in drd1a-eGFP mice (Fig. 
3A). As in the case of drd2-eGFP mice, rostro-caudal quantification of c-Fos-positive 
neurons in the NAc core of drd1a-eGFP mice also showed a large increase of c-Fos 
neurons (266.8 ± 12, n = 4 vs. 20.8 ± 1.6, n = 3, p < 0.0001), suggesting that overall c-Fos 
induction in drd2-eGFP mice was not aberrant. Overall induction of c-Fos was also similar 
to that we have previously reported in other mice using the same treatment protocol 
(Bagley et al., 2011). 
 
As found in the drd2-eGFP mice (see above), a large increase of immunoreactivity (~22 
fold) was found in presumed D2R+ (observed as D1R-) neurons of the NAc core, and a 
much lower and non-significant increase (∼3 fold) in D1R+ neurons after naloxone-
precipitated withdrawal (Fig. 3B). In the NAc shell, naloxone-precipitated withdrawal 
induced a marked increase of c-Fos immunoreactivity in D1R- neurons (~27 fold), although 
a smaller (~7 fold), significant increase of c-Fos immunoreactivity also occurred in D1R+ 
neurons (Fig. 3C). Taking the findings for drd2-eGFP and drd1a-eGFP mice together, these 
results clearly demonstrate that the strong neuronal activation occurring in the NAc 
following naloxone-precipitated withdrawal predominantly involves D2R striatopallidal MSNs 
of the indirect pathway, with a lesser involvement of D1R MSNs. 
 
3.4 Acute morphine treatment induces a selective increase of c-Fos expression in D1R 
population of striatal MSNs 
The sub-populations of NAc MSNs in which c-Fos is induced in response to acute morphine 
have not been studied directly. The distribution of c-Fos induction in response to a single 
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injection of morphine (50 mg/kg) was examined in drd2-eGFP mice (Fig. 4). Two hours after 
injection, morphine-treated mice displayed an increase in c-Fos immunoreactive neurons in 
both the core and shell of the NAc compared to vehicle controls (Fig. 4A), confirming the 
effects of this drug in ventral striatal regions (Garcia et al., 1995; Bontempi and Sharp, 
1997; Taracha et al., 2006). Although significant, the overall induction of c-Fos by acute 
morphine was substantially less than that observed during naloxone-precipitated withdrawal 
(77.9 ± 9.08, n = 4 vs. 35.33 ± 2.4, n = 3, p < 0.05), particularly in the NAc core (Fig. 4B, C). 
Interestingly, co-localization with eGFP revealed that the morphine-induced increase in c-
Fos immunoreactive neurons occurred exclusively in neurons that did not express eGFP 
fluorescence (Fig, 4A). The quantification study revealed that, whereas both eGFP-positive 
(D2R+) and eGFP-negative (D2R-) neurons expressed equivalent basal levels of c-Fos 
immunoreactive neurons, acute morphine treatment increased c-Fos expression selectively 
in D2R- neurons, whereas D2R+ c-Fos levels remained unchanged (Fig. 4B, C). As 
previously reported (Taracha et al., 2006), the extent of neuronal activation was found to be 
higher in the NAc shell, although the distribution of the activated cells was restricted to D2R- 
neurons in both NAc core and shell (Fig. 4B, C). These results suggest the exclusive 
activation of the D1R striatonigral system of the NAc in response to a single injection of 
morphine. 
4. Discussion 
The aim of the present study was to unambiguously identify the sub-populations of MSNs 
activated by naloxone-precipitated opioid-withdrawal, as well as acute morphine, in the NAc 
since both opioid-related conditions generate strong cellular responses in ventral striatal 
neurons despite their very different neurobehavioral effects. To this end, we took advantage 
of the recently generated BAC transgenic reporter mouse lines (Gong et al., 2003), which 
have been shown to be useful for sensitive and selective identification of the two different 
populations of projection MSNs (Bertran-Gonzalez et al., 2008; Matamales et al., 2009).  
Our results confirm previous studies that eGFP labeling in these lines permits reliable 
visualization of virtually all of the D1R and D2R classes of MSNs (Bertran-Gonzalez et al., 
2008, Matamales et al., 2009).  As shown in Fig. 1, drd2-eGFP mice showed that about one 
half of the striatal projection MSNs, which were reliably identified through DARPP-32 
immunodetection, expressed a clear eGFP signal in the core and shell regions of the NAc, 
as expected. This is fully in agreement with previous reports validating in these mice that 
DARPP-32 immunostaining labels all striatal neurons (MSNs) except for local interneurons 
(Bertran-Gonzalez et al., 2008, Matamales et al., 2009). These studies established that 
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approximately a half of DARPP-32 positive (medium spiny) striatal neurons are eGFP 
positive in each of drd2-eGFP and drd1a-eGFP mice and, importantly, that all DARPP-32 
positive neurons are eGFP positive when the two lines are crossed (Matamales et al., 
2009). Using these mice we found a striking segregation between the MSNs engaged by 
withdrawal (predominantly D2R MSNs) and acute morphine (exclusively D1R MSNs), 
respectively.  
The mechanisms responsible for selective engagement of D2R neurons during opioid 
withdrawal are not certain. Although opioid withdrawal directly modulates synaptic activity in 
NAc neurons in vitro (e.g. Chieng and Williams, 1998), most studies suggest that the effects 
of morphine withdrawal in the NAc are a consequence of alterations of dopamine neuron 
firing in the VTA (Williams et al., 2001) and are not due to a local regulation of MOR 
(Maldonado et al., 1992). In contrast to the effects of acute morphine, morphine withdrawal 
induces a profound depression of dopamine neuron activity in the VTA (Diana et al., 1995), 
both through enhanced GABAergic (Madhavan et al., 2010) and decreased glutamatergic 
transmission onto these neurons (Manzoni and Williams, 1999). Opioid withdrawal also 
enhances c-Fos expression in GABAergic VTA neurons (Bagley et al., 2011). An intriguing 
question from these studies is how an abrupt and virtually complete cessation of dopamine 
neuron firing induced by morphine withdrawal (Diana et al., 1995) can lead to such a strong 
neuronal activation in ventral striatal regions (Hayward et al., 1990; Rasmussen et al., 
1995; Georges et al., 2000; Gracy et al., 2001). It is tempting to speculate that nearly 
complete elimination of dopamine release in the NAc during withdrawal removes the 
sustained stimulation of high affinity, inhibitory D2Rs (Richfield et al., 1989). This would be 
expected to trigger the strongly segregated neuronal responses in neurons containing 
D2Rs observed in the present study because the sustained, Gαi-mediated inhibition of 
cAMP signaling by D2Rs would be released, as has been shown to occur in response to 
D2R blockade in the dorsal striatum (Bertran-Gonzalez et al., 2009). 
If the mechanism of selective c-Fos induction in D2R versus D1R MSNs did depend 
indirectly on dopamine tone, this might also explain the selective induction of c-Fos in D1R+ 
after acute administration of morphine. It is generally accepted that acute effects of 
systemic morphine on striatal neurons are the consequence of a strong regulation exerted 
by GABAergic interneurons of the VTA on dopamine neurons through a MOR-dependent 
mechanism (Di Chiara and North, 1992; Johnson and North, 1992). Accordingly, 
systemically administered morphine stimulates MORs strongly expressed in midbrain 
GABAergic synapses, which engages Gαi-mediated intracellular signaling events that 
decrease the GABAergic tone exerted on dopamine neurons of the VTA (Di Chiara and 
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North, 1992; Johnson and North, 1992), presumably arising from local GABAergic 
interneurons (Johnson and North, 1992; Chieng et al., 2011) and GABAergic rostromedial 
tegmental nucleus neurons (Jalabert et al., 2011; Matsui and Williams, 2011). This in turn 
disinhibits dopamine neurons, inducing release of dopamine in target regions such as the 
NAc. Importantly, enhanced dopamine release in the NAc caused by other stimuli produces 
strong c-Fos induction in MSNs, an effect that has been shown to be dependent upon D1- 
and NMDA-receptors (Liu et al., 1994; Bontempi and Sharp, 1997). Since c-Fos expression 
(as well as a multitude of other signaling events; Valjent et al., 2009) is mediated by D1Rs 
in response to drugs increasing dopamine tone, only neurons expressing these receptors 
are expected to be excited after acute morphine administration, as was observed after 
administration of psychostimulants (Bertran-Gonzalez et al., 2008). 
It is difficult to reconcile our findings with the double in situ hybridization study of Georges et 
al. (2000) in morphine-withdrawn rats. In their study, naltrexone-precipitated withdrawal 
induced c-fos mRNA expression with a trend for selective expression in D1R mRNA-
positive and pre-pro-enkephalin A mRNA-negative (striatonigral) neurons of the NAc 
(Georges et al., 2000). Interestingly, however, they reported in the same animals a 
preferential distribution of c-fos mRNA in striatopallidal (presumably D2R positive) neurons 
of dorsal striatal regions. Besides possible differences due to species, the method of MSN 
phenotyping (in situ hybridization vs. targeted expression of eGFP) and/or neuronal activity 
detection (mRNA vs. protein), the different degrees of D1R and D2R co-expression 
reported in different striatal territories may explain the contrasting results (Bertran-Gonzalez 
et al., 2008; Perreault et al., 2010). It is important to consider recent estimates of D1R and 
D2R co-expressing neurons performed in BAC transgenic mice, in which only 5% of the 
MSNs are estimated to co-express these receptors in the dorsal striatum and the NAc core, 
whereas up to 17% of the MSNs seem to do so in the NAc shell (Bertran-Gonzalez et al., 
2008; Matamales et al., 2009). 
Importantly, co-expression D1R and D2R in ~17% of MSNs in NAc shell could also 
reconcile the differences observed here in drd1a- and drd2-eGFP mice following morphine 
withdrawal. A similar induction of c-Fos in D2R expressing neurons was found in the NAc 
core and shell of both drd2-eGFP (D2R+) and drd1a-eGFP mice (D1R-) after precipitation of 
withdrawal. However, withdrawn drd1a-eGFP mice also showed a small, significant 
increase in c-Fos expression in D1R+ neurons of the shell but not the core (see Figs. 2 and 
3). According to the functional model discussed above, the effect induced by morphine 
withdrawal in the NAc would be directly mediated by D2Rs, and should therefore be 
exclusively dependent on the distribution of D2Rs but not D1Rs. Thus, a more accurate 
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localization of the effect is expected in the drd2-eGFP line, which labels all the neurons that 
express D2Rs, independently of their co-expression with D1Rs. By contrast, since the 
levels of D1R and D2R co-expression occur in about 17% of the neurons in BAC-transgenic 
mice (Bertran-Gonzalez et al., 2008; Matamales et al., 2009), the expected proportion of 
D1R+ neurons in drd1a-eGFP mice showing the effect should approach this number, which 
likely corresponds to D1R and D2R co-expressing neurons. New transgenic lines 
accurately labeling both populations with different fluorophores in the same individuals 
already exist, and should help to resolve this question (Shuen et al., 2008; Ade et al., 
2011). 
5. Conclusions 
In conclusion, the present study has identified clearly segregated cellular activation D2R 
and D1R expressing MSNs of the NAc induced by opioid withdrawal and acute morphine, 
respectively. This characteristic pattern of neuronal responses in the NAc is crucial for the 
understanding of the addictive and aversive properties of opioids during acute 
administration and withdrawal, respectively. Both factors contribute to the limitations of 
opioids for the therapeutic treatment of pain disorders.  
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Figure Legends 
Fig. 1. Distribution of eGFP fluorescence in the NAc core and shell of drd2-eGFP BAC 
transgenic mice. (A) Three rostro-caudal coronal sections containing the NAc were selected 
per animal. Red squares indicate the sample regions bilaterally taken from the NAc core (c) 
and NAc shell (s). Coordinates are mm from Bregma (Diagrams modified from Dong, 2008). 
(B) Low-magnification micrograph showing the distribution of drd2-eGFP signal in all striatal 
regions at +1.245 mm from Bregma. Insets 1 and 2 show a higher magnification confocal 
image of the selected regions of the NAc core (1) and NAc shell (2) used in further analyses 
of this study. (C, D) Confocal images showing double staining of the MSN marker DARPP-
32 (red) and drd2-driven eGFP (green) in the NAc core (C) and shell (D). Note that drd2-
driven fluorescence is present in about half of the MSNs. 
 
Fig. 2. Naloxone-precipitated morphine withdrawal induces c-Fos expression almost 
exclusively in D2R-eGFP neurons of the NAc. (A) Over a six-day period, drd2-eGFP mice 
received 300 mg/kg s.c. morphine injections (M, days 1,3,5) and were challenged with no 
injection (control, C), vehicle injection (V, i.p.) or 5 mg/kg naloxone (NLX, i.p.) on day 6. (B) 
Single confocal micrographs showing drd2-driven eGFP fluorescence (green) combined 
with c-Fos immunofluorescence (red) in the NAc core of morphine-treated drd2-eGFP mice 
perfused 2 hours after final treatment. (C, D) Quantification of c-Fos immunoreactive 
neurons among eGFP-positive (D2R+) and eGFP-negative (D2R-) neurons in the NAc core 
(B) and NAc shell (C) of drd2-eGFP mice treated as in A. Data (mean ± SEM; n = 3-4 per 
group) were analyzed using two-way ANOVA with Bonferroni posthoc comparisons. *p < 
0.05; ***p < 0.001; n.s., non significant. 
 
Fig. 3. Naloxone-precipitated morphine withdrawal induces a matching pattern of c-Fos 
expression in drd1a-eGFP mice. drd1a-eGFP mice were treated as in Fig. 2A. (A) Single 
confocal micrographs showing drd1a-driven eGFP fluorescence (green) combined with c-
Fos immunofluorescence (red) in the NAc core of morphine-treated drd1a-eGFP mice 
perfused 2 hours after naloxone (NLX 5 mg/kg) or not (Control). (B, C) Quantification of c-
Fos immunoreactive neurons among eGFP-negative (D1R-) and eGFP-positive (D1R+) 
neurons in the NAc core (B) and NAc shell (C) of drd1a-eGFP mice treated as in A. Data 
(mean ± SEM; n = 3-4 per group) were analyzed using two-way ANOVA with Bonferroni 
posthoc comparisons. ***p < 0.001; n.s., non significant. 
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Fig. 4. Acute morphine treatment induces c-Fos expression exclusively in non D2R-eGFP 
neurons of the NAc. (A) Single confocal micrographs showing drd2-driven eGFP 
fluorescence (green) combined with c-Fos immunofluorescence (red) in the NAc core of 
drd2-eGFP reporter mice 2 hours after a single injection of vehicle or morphine (50 mg/kg, 
s.c.). (B, C) Quantification of c-Fos immunoreactive neurons among eGFP-positive (D2R+) 
and eGFP-negative (D2R-) neurons in the NAc core (B) and NAc shell (C) of drd2-eGFP 
mice treated as in A. Data (mean ± SEM; n = 3-4 per group) were analyzed using two-way 
ANOVA with Bonferroni posthoc comparisons. *p < 0.05; ***p < 0.001; n.s., non significant. 
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 D2R and D1R-GFP transgenics can identify activated (c-Fos) nucleus accumbens neurons 
 Both opioid withdrawal and acute morphine induce c-Fos in nucleus accumbens  
 Morphine withdrawal selectively induces c-Fos in D2R neurons in nucleus accumbens 
 Acute morphine selectively induces c-Fos in D1R neurons in nucleus accumbens   
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